Actinium Pharmaceuticals (ATNM) Stock Price Down 12.2%

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares traded down 12.2% on Friday . The company traded as low as $0.36 and last traded at $0.36. 631,743 shares changed hands during mid-day trading, a decline of 13% from the average session volume of 725,458 shares. The stock had previously closed at $0.41.

Several research firms have recently commented on ATNM. B. Riley began coverage on Actinium Pharmaceuticals in a report on Wednesday, December 6th. They set a “buy” rating and a $2.75 price target on the stock. Zacks Investment Research lowered Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 15th. Finally, Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 27th. Five investment analysts have rated the stock with a buy rating, Actinium Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $3.75.

The stock has a market cap of $32.44, a price-to-earnings ratio of -0.77 and a beta of 40.64.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. D.A. Davidson & CO. boosted its position in Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 157,000 shares of the biotechnology company’s stock after acquiring an additional 109,000 shares during the period. D.A. Davidson & CO. owned 0.20% of Actinium Pharmaceuticals worth $104,000 at the end of the most recent reporting period.

COPYRIGHT VIOLATION WARNING: “Actinium Pharmaceuticals (ATNM) Stock Price Down 12.2%” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply